Scientists zap tumors to boost immune attack on cancer

NCT ID NCT02642809

Summary

This small, early-stage study tested a two-part treatment for advanced esophageal cancer that had spread. First, doctors used a short, intense course of targeted radiation on the main tumor in the esophagus. The goal was to 'wake up' the patient's own immune system to fight the cancer. Then, they gave an immunotherapy drug (pembrolizumab) to help the immune system attack cancer cells throughout the body. The main goal was to see if this combination was safe for patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.